Search
Plant-based virus-like particles, recombinant, adjuvanted COVID-19 vaccine
go.drugbank.com/drugs/DB16757Approved[L40694] It is composed of VLPs expressing SARS-CoV-2 spike protein trimers (stabilized in a pre-fusion conformation) and is mixed with the AS03 adjuvant system prior to administration. … The Covifenz COVID-19 vaccine (plant-based virus-like particles (VLP), recombinant, adjuvanted) is a plant-based vaccine developed in partnership by Medicago and GlaxoSmithKline which is approved in Canada
Synonyms: Recombinant SARS-CoV-2 spike (S)-protein virus-like particleNitroglycerin
go.drugbank.com/drugs/DB00727ApprovedInvestigationalNitroglycerin, also known as glyceryl trinitrate,[A180169] is an organic nitrate and a vasodilating agent [L38369] that was first discovered in 1847. … [A249970] Nitroglycerin causes vasodilation in both arteries and veins.
Mixtures: NITROGLICERINA 0.1 MG/ML EN DEXTROSA 5% SOLUCION INYECTABLE, Nitroglycerin In 5% Dextrose Inj.-400mcg/mlCategories: Vasodilators Used in Cardiac Diseases, Compounds used in a research, industrial, or household settingDarbepoetin alfa
go.drugbank.com/drugs/DB00012ApprovedInvestigationalHuman erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Products: ARANESP® 100µG SOLUCION INYECTABLE EN JERINGA PRELLENADA, ARANESP® 50 MCG SOLUCIÓN INYECTABLE EN JERINGA PRELLENADAFulvestrant
go.drugbank.com/drugs/DB00947ApprovedInvestigationalIt is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. … Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy.
Products: FULVESTRANT 250 MG/5ML SOLUCION INYECTABLE EN JERIGA PRECARGADA, FULTRANT ® 250MG/ 5ML SOLUCIÓN PARA INYECCIÓN EN JERINGA PRELLENADABudesonide
go.drugbank.com/drugs/DB01222ApprovedInvestigational[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994.[L10598] It is also available in a combination product with [formoterol].[L10619]
Mixtures: BUDESONIDE E FORMOTEROLO SANDOZ, BUDESONIDE E FORMOTEROLO SANDOZProducts: Budo-San 3 mg - Kapseln, BUDESONIDA 50 MCG INHALADOR EN AEROSOLTrabectedin
go.drugbank.com/drugs/DB05109ApprovedInvestigationalTrabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. … Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer.
Products: TRABECTEDINA EG, Trabectedin TEVA 0,25 mg Pulver für ein Konzentrat zur Herstellung einer InfusionslösungOctasulfur
go.drugbank.com/drugs/DB09353ApprovedAfter calcium and phosphorus, it is the third most abundant mineral in the human body. Sulfur is also found in garlic, onions and broccoli. … Sulfur seems to have an antibacterial activity. It has been also used for acne.
Mixtures: Spai-Sons Calendula/Marigold, Avar-eProducts: End-zit, Spai-sons Marigold Oily SkinGlycerin
go.drugbank.com/drugs/DB09462ApprovedInvestigationalA trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism.
Mixtures: Cellmov Cell Line Mask, Cellisys EX Wrinkle SolutionCategories: Compounds used in a research, industrial, or household settingTranexamic acid
go.drugbank.com/drugs/DB00302ApprovedInvestigational[L31883] It was first patented in 1957[A230108] and received its initial US approval in 1986.[L31858] … Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding.
Products: Tranexamsäure Sanus 100 mg/ml Injektionslösung, ACIDO TRANEXAMICO EGPancrelipase
go.drugbank.com/drugs/DB00085ApprovedInvestigational[L2510] For further information on the components of this mixture please visit [DB11065], [DB11066] and [DB13147]. … [L2509] The pancrelipase mixture was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.
Products: KREON 20000PH EU LI EI HKM, KREON 35000 PH EUR LIP EI